DUBLIN, Ireland--(BUSINESS WIRE)--Results from the first-ever study directly comparing the effectiveness of once-monthly extended-release naltrexone (VIVITROL ®) to daily buprenorphine-naloxone in ...

Please provide your email address to receive an email when new articles are posted on . In a randomized clinical trial and follow-up study, treatment with combined buprenorphine-naloxone demonstrated ...

Credit: Getty Images. Buprenorphine-naloxone may be more cost-effective than extended-release naltrexone as first-line treatment for opioid use disorder. Buprenorphine-naloxone may be more ...

Please provide your email address to receive an email when new articles are posted on . Switching from buprenorphine-naloxone to extended-release naltrexone did not induce or increase pain in people ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...

Forbes contributors publish independent expert analyses and insights. I write about issues at the intersection of medicine and culture. Now comes a provocative new study by economists Jennifer Doleac ...

MALVERN, PA / ACCESSWIRE / August 13, 2019 / Virpax ® Pharmaceuticals, Inc. (“Virpax”), a company specializing in developing pharmaceutical products for pain management, announced today that it ...

A non-narcotic pharmaceutical that blocks opioid receptors in the brain so that opioids will not provide any effect. Its injectable form is Vivitrol, and it is given monthly. It can be prescribed in a ...

The guideline on the management of opioid use disorders by Bruneau and colleagues1 is excellent; however, they omitted monthly injectable naltrexone. The authors did review use of the oral formulation ...